default author photo

Maisam Makarem

Harvard University - Dana-Farber Cancer Institute

Boston, MA

United States

SCHOLARLY PAPERS

1

DOWNLOADS

83

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older with Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in Pd-L1 High (≥50%) Patients

Number of pages: 35 Posted: 03 Jan 2025
Harvard University - Dana-Farber Cancer Institute, affiliation not provided to SSRN, Harvard University - Dana-Farber Cancer Institute, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Imperial College London, affiliation not provided to SSRN, affiliation not provided to SSRN, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, University of California, Los Angeles (UCLA), Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, affiliation not provided to SSRN, MD Anderson Cancer Center - Department of Gastroenterology, Hepatology and Nutrition, affiliation not provided to SSRN, University of Kansas - Cancer Center, University of Kansas - University of Kansas Medical Center, Vanderbilt University, Vanderbilt University - Medical Center, Imperial College London, Harvard University - Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute and University of Oklahoma - Stephenson Cancer Center
Downloads 83 (783,685)

Abstract:

Loading...

Non-Small Cell Lung Cancer, immunotherapy, pembrolizumab, Tumor microenvironment, Tumor immunophenotype, Older adults